It is a challenge to evaluate experimental treatments where it is suspected that the treatment effect may only be strong for certain subpopulations, such as those having a high initial severity of disease, or those having a particular gene variant. Standard randomized controlled trials can have low power in such situations. They also are not optimized to distinguish which subpopulations benefit from a treatment. With the goal of overcoming these limitations, we consider randomized trial designs in which the criteria for patient enrollment may be changed, in a preplanned manner, based on interim analyses. Since such designs allow data-dependent changes to the population sampled, care must be taken to ensure strong control of the familywise Type I error rate. Our main contribution is a general method for constructing randomized trial designs that (1) allow changes to the population enrolled based on interim data, using a prespecified decision rule, (2) make no parametric model assumptions, and (3) guarantee the asymptotic, familywise Type I error rate is strongly controlled at a specified level α. As a demonstration of our method, we prove new, sharp results for a simple, two-stage enrichment design. We then compare this design to a fixed design, focusing on each design's ability to determine overall and subpopulation specific treatment effects.
Introduction
Randomized trial designs in which participants are enrolled sequentially over time, and where interim analyses are done at prespecified points during the trial, are called group sequential designs. We consider settings where follow up time is relatively short. At interim analyses, it is then possible to look at outcome data from the patients who have already completed the trial, and use this to optimize aspects of the trial design.
We focus on designs that allow preplanned changes to the population enrolled, based on interim analyses. Such designs, called enrichment designs, may be useful when it is thought that the effect of a treatment may differ in certain subpopulations. For example, these could be subpopulations defined by a genomic biomarker measured at baseline such as human epidermal growth factor receptor-2 in studies of breast cancer therapies (Baselga, 2001; Wang et al., 2007 Wang et al., , 2009 , or defined by baseline factors such as initial severity of depression in studies of antidepressants (Kirsch et al., 2008) . In both examples, there is evidence that certain subpopulations, i.e. those with higher levels of the biomarker, and those with high baseline severity of depression, respectively, may benefit more from specific interventions. As we show below, designs that allow preplanned changes to which subpopulations are enrolled can lead to more power, and can reveal more information about subpopulation specific treatment effects.
As a concrete example, consider designing a study to test the effectiveness of a hypothetical new antidepressant. Kirsch et al. (2008) present suggestive, though not conclusive, evidence that certain commonly prescribed antidepressants may only be effective for those with severe, rather than moderate, depression at study baseline. With this in mind, it may be advantageous to incorporate the following preplanned interim analysis in one's trial of the new antidepressant: if it is observed that the treatment effect is sufficiently low among those with moderate baseline depression, one will enroll only those with severe baseline depression for the rest of the trial. We show in Section 4 that certain designs of this type can give improved power, compared to a standard fixed design, at certain alternatives of interest. By standard fixed design, we mean a design that does not allow changes to the population enrolled, and that uses a one-sided z-test for comparing two means with a fixed sample size. Due to the multiple hypotheses potentially tested in an enrichment design, a major methodological challenge for such designs is guaranteeing strong control of the familywise Type I error rate.
Our main contribution is a general method for computing the asymptotic, worst-case, familywise Type I error rate for a wide range of enrichment designs. This is of interest, in particular, to the U.S. Food and Drug Administration, who state in a recent draft guidance (FDA, 2010 ) that for trials allowing certain interim modifications such as those discussed in this paper, "The chief concerns with these designs are control of the study-wide Type I error rate, minimization of the impact of any adaptation-associated statistical ... or operational bias on the estimates of treatment effects, and the interpretability of trial results." We focus throughout this paper on strong control of the familywise Type I error rate, as defined by (Hochberg & Tamhane, 1987, pp. 3, 7) , and only consider designs that guarantee clear interpretability of trial results. We briefly discuss the important topics of estimation and confidence intervals in Section 6.
The familywise Type I error rate is the probability that at least one true null hypothesis is rejected. Throughout, we slightly abbreviate familywise Type I error rate by familywise Type I error. The worst-case, familywise Type I error is the supremum over all possible data generating distributions of the familywise Type I error. The asymptotic, worst-case, familywise Type I error is the limit of this supremum as sample sizes in all stages of a given design go to infinity, which we formally define in Section 5.4. When we say a study design strongly controls the asymptotic, familywise Type I error at level α, we mean the corresponding asymptotic, worst-case, familywise Type I error is at most α.
Even in some relatively simple enrichment designs, such as those we present in Section 3, it is difficult or impossible to analytically determine the asymptotic, worst-case, familywise Type I error. To address this, we present a general theorem that reduces this problem for a given design to a more convenient optimization problem, that often can be exactly solved by standard software. We apply this theorem to the class of enrichment designs in Section 3, leading to new results on familywise Type I error control for these designs.
Throughout this paper, we only consider designs with preplanned rules for changing the population enrolled, based on interim data. We do not consider designs that adapt the total sample size, the number of treatment arms, or the randomization probabilities, for example. However, it is possible to apply our general method to designs that involve such adaptations, and this is an area for future research.
Related Work
Methods have been proposed to deal with the multiple testing problem that arises from design adaptations in which the study population, study treatment, or study endpoint may be changed, e.g. (Thall et al., 1988; Schaid et al., 1990; Bauer & Köhne, 1994; Follmann et al., 1994; Follmann, 1997; Russek-Cohen & Simon, 1997; Kieser et al., 1999; Hommel, 2001; Stallard & Todd, 2003; Sampson & Sill, 2005; Bischoff & Miller, 2005; Jennison & Turnbull, 2006 Wang et al., 2007 Wang et al., , 2009 . In many cases these methods lead to sharp bounds on familywise Type I error. However, for the class of designs we give in Section 3 these methods either do not apply or our method gives improved results.
Below, we describe the following related work that is especially relevant to the class of designs we present in Section 3: (Thall et al., 1988; Bauer & Köhne, 1994; Follmann, 1997; Russek-Cohen & Simon, 1997; Kieser et al., 1999; Wang et al., 2007 Wang et al., , 2009 . Each of these papers incorporates a preplanned interim analysis that can result in a change in the data generating distribution for the second stage, and a method for ensuring familywise Type I error is controlled. Thall et al. (1988) consider the problem of estimating the effect of the best treatment among a set of k prespecified treatments. They use a two stage design that drops all but the single best performing treatment after an interim analysis. Their method can be modified to apply in the setting of this paper, where rather than selecting which treatment to continue in stage two, we select which population to continue enrolling in stage two. The Type I error guarantees of Thall et al. (1988) do not carry over to our setting, however, for two reasons. First, while in our setting it is important to be able to enroll from multiple subpopulations in stage two, this is not allowed in the analogous designs of Thall et al. (1988) ; this makes sense, since their goal was selecting the single best treatment. Second, their designs use a different final test statistic than we do. Bauer & Köhne (1994) and Kieser et al. (1999) present a general multiple testing procedure that can be applied to designs where the subpopulations enrolled can be changed based on interim analyses. This procedure is an important advance, and is based on the closed testing principle (Marcus et al., 1976) , as well as combining p-values from each stage using a prespecified combination rule. Application of their method to our class of designs in Section 3, however, gives a multiple testing procedure with strictly lower power than the one resulting from application of our general method from Section 5. Follmann (1997) proves control of Type I error for a large class of useful enrichment designs. This class of designs allows a much wider range of decision rules than the ones we consider in Section 3. However, in (Follmann, 1997) , the only null hypothesis tested is the global null hypothesis that neither subpopulation benefits from treatment. In contrast, we test null hypotheses corresponding to the overall population as well as specific subpopulations. The advantage of testing more than the global null hypothesis is that rejecting it does not permit one to draw conclusions about treatment effects in a specific subpopulation or in the total population. This is because the complement of the global null hypothesis is that there is a positive effect in at least one subpopulation; without further tests or assumptions, one cannot directly conclude which subpopulation this is, nor determine whether there is a net positive effect in the total population.
Russek-Cohen & Simon (1997) present a novel two stage adaptive design that incorporates a test for a subpopulation by treatment interaction, which is used to determine the sample size in the second stage. Their designs have good power in many scenarios, though not when using one-sided tests as done here. A difference between their work and this paper is they do not prove strong control of familywise Type I error for their designs, which is a main contribution of this paper for the designs we present. Wang et al. (2007 Wang et al. ( , 2009 propose important enrichment designs using decision rules similar to those we give in Section 3. However, in (Wang et al., 2007) , the focus is on testing the null hypothesis associated with a single subpopulation; their designs have more power than ours for detecting an effect in this single subpopulation, but less power than our method for testing the null hypothesis for the total population. The setup in Wang et al. (2009) differs from ours in that they assume if there is no net positive effect in the overall population, then there is no net positive effect in a certain, prespecified subpopulation; we do not make that assumption here.
A Class of Enrichment Designs

Overview
We present a class of two stage, enrichment designs tailored to the problem described in Section 1, of testing the effectiveness of a hypothetical new antidepressant. The aim of these designs is to improve power and better determine subpopulation specific treatment effects. To the best of our knowledge, our general method gives the first means of precisely computing the asymptotic, worst-case, familywise Type I error of these enrichment designs. This can be used to determine the subclass of such designs that strongly control familywise Type I error at a desired level, e.g. 0.05; we can then compare these designs to fixed designs of the same total sample size, in terms of overall power and ability to determine subpopulation specific treatment effects. Later, in Section 4, we present a simple enrichment design from our class that improves on a standard fixed design at certain alternatives of interest.
As described above, Kirsch et al. (2008) present suggestive, but not conclusive, evidence from a meta-analysis that a class of commonly used antidepressants may not be superior to placebo for those with moderate pretreatment depression, while they are superior to placebo for those with severe pretreatment depression. We consider a method for designing a trial of a hypothetical new antidepressant with this in mind.
For each subject, the Hamilton Rating Scale of Depression score is recorded at baseline and after a set period of time. We refer to a subject's Hamilton Rating Scale of Depression scores simply as his/her scores. Lower scores indicate lower severity of depression. For each subject, we define his/her improvement to be baseline score minus end of study score. If a subject's score increases by the end of study, his/her improvement has a negative value.
We refer to the set of subjects with moderate depression at baseline as subpopulation 1 and refer to the set of subjects with severe depression at baseline as subpopulation 2. We refer to the union of subpopulations 1 and 2, i.e. those with either moderate or severe pretreatment depression, as the total population. Let H 01 denote the null hypothesis that for subpopulation 1, the mean improvement under the new treatment is less than or equal to the mean improvement under the placebo. In an analogous manner, define the null hypothesis H 02 corresponding to subpopulation 2, and the null hypothesis H 00 corresponding to the total population. We emphasize that H 00 is not the intersection of the null hypotheses H 01 and H 02 ; it is the null hypothesis corresponding to the total population, which is the union of the two subpopulations. The alternative hypotheses to H 00 , H 01 , H 02 are that the mean improvement under treatment is greater than under placebo, for the total population, for subpopulation 1, and for subpopulation 2, respectively. Though our designs are motivated by the above application, they can be useful in many situations where the population enrolled consists of two non-overlapping subpopulations of interest, e.g. defined in terms of a genetic marker or a risk score at baseline.
Each participant enrolled is randomly assigned to the study arm or the control arm with 50% chance of being assigned to each. For simplicity, we assume exactly 50% of participants in each subpopulation are assigned to each arm, which can be approximately ensured using stratified block randomization. Also, for simplicity, we assume the total number of subjects to be enrolled in stage one and in stage two is prespecified and cannot be changed. At the end of stage one, we compute three z-statistics, T
(1)
2 , corresponding to the standardized difference in mean improvement between treatment and control groups for subjects in the total population, in subpopulation 1, and in subpopulation 2, respectively; let T (1) 3 denote a prespecified vector of additional stage one statistics. These are defined formally below. We assume that data on all subjects from stage one are available at the interim analysis.
We allow a decision to be made at the end of stage one, based on a prespecified decision rule. We denote this decision rule, which maps the data collected in stage one to a choice for which subpopulation to sample from in stage two, by D. We consider a class of decision rules, denoted by D, that are Borel measurable maps from the above stage one statistics (T 0 for the total population is above a prespecified threshold, and to use option (ii) otherwise. Figure 1 gives a flow chart representing this type of decision rule. Another decision rule, suggested by a reviewer, is to base the decision between options (i) and (ii) on a prespecified test for interaction; if the test rejects, one uses option (ii), and otherwise one uses option (i). The standard fixed design, which corresponds to always choosing option (i), is also a decision rule in the class D.
At the end of the trial, a preplanned final test statistic is computed leading to possible rejection of one of the null hypotheses {H 00 , H 01 , H 02 }. This final test statistic is a weighted combination of the z-statistic T (1) 0 from the first stage using all first stage data from both subpopulations, and the z-statistic from the second stage using all second stage data. The corresponding weights are defined below. If the final test statistic exceeds a threshold c, we reject the null hypothesis corresponding to the subpopulation, or the total population, selected for enrollment in stage two.
Formal definition of statistics, assumptions, and testing procedure
We now precisely define the statistics used in the above decision rules and to test the family of null hypotheses {H 00 , H 01 , H 02 }. We denote the data for subject m by (I m , S m , A m , Y m ); this includes the stage the subject entered the trial I m ∈ {1, 2}, and the subject's subpopulation S m ∈ {1, 2}, study arm assignment A m ∈ {0, 1}, and outcome Y m ∈ R, respectively.
We assume in each stage, for each subpopulation sampled in that stage, that an equal number are assigned to each study arm. However, it is possible to relax this assumption. We assume for each subject, that conditioned on the subject's subpopulation s and study arm assignment a, his/her outcome Y is drawn from an unknown data generating distribution Q sa independent of the other subjects' data. The only assumptions we make on the data generating distributions Q sa are that there exists a γ > 0 and M > 0 that do not depend on sample size, such that the support of Q sa is on [−M, M ] and the variance σ 2 (Q sa ) of Q sa is at least γ. Let n i denote the total number of subjects in stage i, which is preplanned. We require that the fraction of subjects in the first stage n 1 /(n 1 + n 2 ) be between 0.05 and 0.95. We also make an assumption about the fraction of stage one subjects who are from each subpopulation s ∈ {1, 2}, which we denote p s . We consider each p s fixed, i.e. non-random, and unknown, since in practice one may not know in advance how many subjects will enroll from each subpopulation. However, we assume there is a non-negligible fraction of subjects in stage one from each subpopulation; that is, we assume for some τ > 0 not depending on the sample size, that for each s, p s > τ .
Define the stage one z-statistics for subpopulation 1, subpopulation 2, and the total population, respectively, as
where the se i are defined by
Here, se i is the standard error for the corresponding sum in the definition of T
i , conditioned on sample sizes in each subpopulation and treatment category. For simplicity we assume these variances are known, though we allow them to differ by subpopulation and treatment category. It is possible to extend our results to the more realistic case where these variances are estimated.
Let T
(1) 3
denote an additional, prespecified vector of stage one statistics. We put no constraints on T
except that it is a prespecified, Borel measurable map from the stage one data to R k . We now describe the final test statistic and the rejection region for each null hypothesis. After stage two is completed, we compute the following z-statistic based on all the data from that stage:
where se 3 is the standard error for the corresponding sum, conditioned on the enrollment decision made just after stage one, defined analogously as (4) and (5); we defer the formal definition of se 3 to Section C of the Supplementary Material. We reject the null hypothesis corresponding to the subpopulation, or the total population, enrolled in stage two, if the following weighted combination of z-statistics from both stages:
exceeds c for some prespecified threshold c. That is, if both subpopulations are enrolled in stage two and (7) exceeds c, we reject H 00 ; if only subpopulation 1 is enrolled in stage two and (7) exceeds c, we reject H 01 ; if only subpopulation 2 is enrolled in stage two and (7) exceeds c, we reject H 02 . We define our class of enrichment designs to be those that use a decision rule D ∈ D, the z-statistics defined above, and the rejection rule defined in the previous paragraph.
Application of general method from Section 5 to above class of designs
The general method we present in Section 5 allows one to compute, for each enrichment design in the class defined above, the minimum threshold value c for the final test statistic (7) that guarantees strong control of the asymptotic, familywise Type I error at a given level α. This is useful since it is quite difficult, if not impossible, to determine this minimum threshold value c analytically. Our general method gets around this obstacle by reducing this problem to an optimization problem that can be solved numerically with standard software, to any desired precision. This general method can be applied to a wide variety of designs, not only to those considered above.
We obtain, as shown in Section 5 and Sections B-E of the Supplementary Material, that under the above assumptions, for any decision rule D ∈ D, that the minimum threshold value c that guarantees strong control of the asymptotic, familywise Type I error at level α = 0.05 is Φ −1 (0.95), for Φ the cumulative distribution function of the standard normal. This is exactly the same threshold as would have been used in a standard fixed design, with no preplanned change. This is surprising, since allowing designs that adapt to accrued data has the potential to result in Type I error inflation. We show for the above class of enrichment designs that no such inflation can occur, at least asymptotically. Thus, the above class of designs allows flexibility at no price in terms of a stricter rejection threshold. Furthermore, in Section 4 we show one such design that provides a substantial gain in the probability of correctly detecting an effect when it exists in just one subpopulation, compared to a fixed design, though there is some price paid when there is an effect in both subpopulations.
In the above class of enrichment designs, all the first stage data from both subpopulations is used in the final test statistic (7), even when the final hypothesis tested concerns only one of these subpopulations. Though this may initially appear odd, since data from one subpopulation may influence whether the null hypothesis for the other subpopulation is rejected, this is a property shared by virtually all procedures for controlling familywise Type I error, with an exception being the conservative procedure of Bonferroni; for example, this property holds for the closure principle of Marcus et al. (1976) , the step-down procedure of Holm (1979) , and the step-up procedure of Hochberg (1988) .
To explain the intuition behind why the above class of designs can be advantageous, consider the case where subpopulation 2, which consists of those with severe depression at baseline, has the larger corresponding z-statistic in stage one, and enrollment is from only this subpopulation in the second stage. Then the null hypothesis tested at the end of the study is H 02 , the null hypothesis of no mean treatment effect in subpopulation 2. If we were to test H 02 based only on the data from subpopulation 2, thereby throwing out the stage one data for subpopulation 1, this would introduce a selection bias due to essentially hiding data that was unfavorable. A correction can be done to account for this, by raising the threshold that the final test statistic must exceed before the null hypothesis H 02 is rejected, as is done in a similar situation in (Thall et al., 1988) . In contrast, our testing procedure does not require any such raised threshold; the reason, intuitively, is that our test statistic already includes the penalty of having to incorporate data from the subpopulation that had a weaker signal. This intuitive argument is proved rigorously in Sections B-E of the Supplementary Material. It is an area of further research to compare our designs to ones that throw out data from discontinued subpopulations and correct for the resulting selection bias by incorporating a prespecified penalty.
Power Comparison between adaptive design from Section 3 and fixed designs
We show in Section 5 and Sections B-E of the Supplementary Material that for each decision rule in the class D given above, the resulting adaptive design guarantees strong control of asymptotic, familywise Type I error at level α = 0.05, when the rejection threshold c for the final statistic (7) is set to Φ −1 (0.95). Having shown the validity of such enrichment designs in terms of Type I error control, we now consider their power. We present a particular design from the class D, and compare its power to that of two different fixed designs under several scenarios. We continue to use the example introduced in Section 3 of testing a hypothetical new antidepressant, motivated by the meta-analysis of Kirsch et al. (2008) . We let subpopulation 1 denote those with moderate pretreatment depression, and subpopulation 2 denote those with severe pretreatment depression.
To specify a particular adaptive design from the class in the previous section, we need to choose a decision rule D ∈ D. Recall that each D ∈ D is a function from the stage one statistics to two possible choices for stage two enrollment: (i) enroll from both subpopulations as in stage one or (ii) enroll only from the subpopulation corresponding to the larger of the stage one z-statistics T 
2 . We define our decision rule, which we denote byD, to choose option (i) if the z-statistic T (1) 1 > 0.3, then there is at least some hope that the treatment is effective for subpopulation 1, i.e. for those with moderate pretreatment depression. In this case, we continue enrolling them, as well as those from subpopulation 2, in stage two. Otherwise we give up on subpopulation 1 and only enroll from subpopulation 2 for the rest of the trial. We next explain how we chose the threshold of 0.3.
Since the above design is in the class D, the asymptotic, familywise Type I error is strongly controlled, as described above. Consider replacing the threshold 0.3 above by any other prespecified threshold. Since the resulting design remains in the class D, the same familywise Type I error guarantee holds. It is therefore possible to examine various threshold values, and select based on which one gives the most power in scenarios of interest. We selected the threshold 0.3 to give a good tradeoff in power in the scenarios considered below.
In Section I of the Supplementary Material we compare the familywise Type I error and power of this enrichment design to two fixed designs, under a variety of scenarios. We present six such scenarios here, which we number 1a, 1b, 1c, 2a, 2b, 2c. In all scenarios and all designs, the total sample size is the same: 488 subjects. In scenarios 1a, 1b, 1c, we assume half of the subjects enrolled in stage one are from subpopulation 1, and the other half are from subpopulation 2. In scenarios 2a, 2b, 2c, we assume 75% of the subjects enrolled in stage one are from subpopulation 1, and the other 25% are from subpopulation 2.
We consider two fixed designs, each of which uses a different multiple testing procedure. In each of these fixed designs, the proportion of subjects enrolled from subpopulation 1 is the same in both stages. At the end of the trial, a p-value corresponding to H 00 is computed based on a one-sided z-test using all the data, comparing treatment to control; a p-value corresponding to H 02 is computed based on a one-sided z-test using only subpopulation 2 data. The first of the multiple testing procedures is a fixed sequence procedure (Maurer et al., 1995) . It rejects H 00 whenever the p-value corresponding to H 00 is less than 0.05; if in addition the p-value corresponding to H 02 is less than 0.05, the null hypothesis H 02 is also rejected. We refer to this design as the fixed sequence design. The second multiple testing procedure is a Hochberg step-up procedure (Hochberg, 1988) . It rejects both null hypotheses H 00 and H 02 if both of the corresponding p-values are less than 0.05; otherwise, if the smallest of these two p-values is less than 0.025, the corresponding null hypothesis is rejected. It is straightforward to prove for these two procedures that the asymptotic, worst-case, familywise Type I error is at most 0.05, under the assumptions in Section 3.2.
Recall that we defined the standard fixed design to not allow changes to the population enrolled, and to use a onesided z-test for comparing two means to test just the null hypothesis for the total population H 00 . By construction, the power of the fixed sequence design dominates the power of the standard fixed design; i.e. for any data generating distribution, the probability that the fixed sequence design rejects H 00 equals that of the standard fixed design, while the fixed sequence design may reject H 02 as well. Since for both these designs the asymptotic, worst-case, familywise Type I error is 0.05, we chose to use the fixed sequence design in our simulations, as it the more powerful of the two designs.
For the adaptive design, we slightly improve the hypothesis testing procedure given in Section 3.2, by incorporating a fixed sequence testing procedure into it. Recall that the testing procedure in Section 3.2 was to reject the null hypothesis corresponding to the subpopulation, or total population, enrolled in stage two if the final statistic (7) exceeds Φ −1 (0.95). We modify this analysis procedure so that whenever the null hypothesis H 00 is rejected, we additionally reject H 02 if the z-statistic combining all subpopulation 2 data from both stages:
exceeds Φ −1 (0.95) + 0.055, where v = (p 2 /2)(n 1 + n 2 ) σ 2 (Q 20 ) + σ 2 (Q 21 ) . We show in Section F of the Supplementary Material that the asymptotic, worst-case, familywise Type I error of this modified procedure is 0.05, for the adaptive design using decision ruleD, for the stage one proportion of subjects enrolled from subpopulation 1 as in the scenarios considered here, and under the assumptions in Section 3.2.
In scenarios 1a and 1b, we use data generating distributions for each subpopulation constructed to reflect what was seen in the meta-analysis of Kirsch et al. (2008) , i.e. no effect of the treatment compared to placebo in those with moderate initial depression, but a mean improvement r > 0 comparing treatment vs. placebo in those with severe initial depression. In scenario 1a, this mean improvement r is set to be 1.8 points, which is the point estimate of this quantity in (Kirsch et al., 2008) ; in scenario 1b, the mean improvement r is set to the more optimistic value of 3 points, which was seen in (Kirsch et al., 2008) for subjects with very severe initial depression. In scenario 1c, we use data generating distributions where the treatment is equally effective for both subpopulations, with the mean improvement in treatment over placebo set to 1.8 points. Scenarios 2a, 2b, and 2c are exactly the same as the corresponding scenarios 1a, 1b, and 1c, respectively, except that in scenarios 2a, 2b, and 2c, 75% of the population enrolled in stage one is from subpopulation 1 rather than 50%.
Other parameters of the data generating distributions, such as the variance in each arm, were based on the estimates of these quantities in Kirsch et al. (2008) . Total sample size in each design was set to be 488 subjects, in order to provide 80% power to the fixed design under scenario 1c. For each scenario, and for both the adaptive design and the fixed design, 100,000 simulated trials were run. See Section H of the Supplementary Material for full details of how the data generating distributions for each scenario are defined, and for the R code used in the simulations.
In each scenario and for each design, the proportion of simulated trials leading to rejection of each null hypothesis among H 00 , H 02 was recorded; by construction, none of the designs ever rejects the null hypothesis H 01 , so it is not considered here. Figure 2 shows, for each scenario, side-by-side bar plots of the probability that each null hypothesis is rejected; the bar on the left is for the fixed design using the fixed sequence multiple testing procedure, the middle bar is for the fixed design using the Hochberg multiple testing procedure, and the bar on the right is for the adaptive design. Each bar has a portion shaded to indicate the proportion of simulated trials in which only null hypothesis H 02 , only null hypothesis H 00 , or both of these simultaneously, are rejected; these are depicted by no shading, stripes, and black shading, respectively.
The fixed design using the fixed sequence multiple testing procedure can lead to rejection of H 00 , to rejection of both H 00 and H 02 , or to no rejection at all; therefore, each corresponding bar consists of a striped component and a black shaded component, representing the proportion of simulated trials in which just H 00 was rejected, and in which both H 00 and H 02 were rejected, respectively. The fixed design using the Hochberg multiple testing procedure, as well as the adaptive design, can lead to rejection of H 00 , H 02 , both simultaneously, or neither, and therefore the corresponding bars have all three types of shading.
Consider the six scenarios depicted in Figure 2 , from left to right. We call the probability of rejecting at least one of H 00 , H 02 , when both are false, the overall power. In all the scenarios depicted in Figure 2 , both of these null hypotheses are false.
We summarize the tradeoffs in using each of the three designs in the scenarios considered above. In all the scenarios, the overall power of the adaptive design was at least as large as that for the other designs. Compared to the fixed sequence design, the improvement in overall power from using the adaptive design ranged from 0 to 43%, depending on the scenario. One drawback of the adaptive design, however, occurs in the scenarios where the treatment is equally effective for both subpopulations, i.e. scenarios 1c and 2c, where it is preferable to reject the null hypothesis for the total population H 00 ; though the overall power of the the adaptive design and the fixed sequence design are equal in these scenarios, the adaptive design has 9% less power for the null hypothesis H 00 . Comparing the adaptive design to the fixed design using the Hochberg procedure, the overall power is similar in scenarios 1a and 1b, but the adaptive design has more overall power in all the other scenarios, with the maximum overall power difference being 12%. The fixed design using the Hochberg procedure has a similar drawback as the adaptive design in the scenarios where the treatment is equally effective for both subpopulations.
General Method and Theorem
Overview
Our main theorem allows one to reduce the problem of computing the asymptotic, worst-case, familywise Type I error of a wide variety of hypothesis tests in adaptive designs to a manageable optimization problem. Before presenting our main theorem, we describe the following: the components of the design that must be prespecified; the data generating distributions and statistical model; the definition of asymptotic, worst-case, familywise Type I error; our assumptions on the statistics used; and the intuition behind the theorem. We focus only on two stage designs below, for clarity. It is straightforward to generalize these definitions, assumptions, and our main theorem to designs with any number of stages. The theorem below can be easily generalized to apply to designs that incorporate adaptations in addition to changing the population sampled, such as changes to sample size and to randomization probabilities, but we do not present such designs here.
Items requiring prespecification
We require the following to be prespecified in any design we consider:
1. a finite set of subpopulations of interest S, and a finite set of treatment arms A.
2. the total number of subjects to be enrolled in each stage i, denoted by n i . We assume there is a positive constant r, independent of sample size, such that n 2 = rn 1 . We let n = (n 1 , n 2 ).
for each stage i, a vector T (i) of statistics taking values in
is a function only of the stage i data and the enrollment decisions made before stage i.
4. a randomization procedure, specifying the probability that each subject is assigned to each treatment arm. We allow this procedure to be standard randomization, block randomization, stratified randomization, or an adaptive method of randomization.
5. a finite set E of potential enrollment procedures for stage two, each of which specifies the proportion of stage two subjects to enroll from every subpopulation. We assume, for each enrollment procedure in E, that one can enroll in stage two to exactly achieve these proportions.
6. a decision function D that maps each value of the vector of stage one statistics T (1) to an element in the set E of potential enrollment proportions for each subpopulation for stage two. We restrict the complexity of the decision rule in the following sense: we require that for each possible enrollment procedure ∈ E, the set of values D −1 ( ) of the statistics T (1) leading to this choice is a finite union of Borel measurable, convex subsets of R t1 .
7. A set of null hypotheses {H 0j } j∈J to be tested, and for each one, a corresponding rejection region R j ⊆ R t1+t2 . Each null hypothesis H 0j represents the subset of the possible data generating distributions Q, defined below, for which this null hypothesis is true. We denote the set of rejection regions for the null hypotheses by {R j } j∈J , and require that each rejection region R j is a finite union of Borel measurable, convex subsets of R t1+t2 . At the end of study, we reject all null hypotheses H 0j for which T
(1) , T (2) ∈ R j .
Data generating distributions and statistical model
We assume that for each subject, conditioned on the subject's subpopulation s and study arm assignment a, his/her outcome Y is a random draw from an unknown data generating distribution Q sa . We assume each such random draw is independent of the subpopulations, treatment assignments and outcomes of all the other subjects. For ease of reference, we denote the set of data generating distributions Q sa by Q = {Q sa } a∈A,s∈S . We assume that Q is an element of a statistical model Q . This may be a nonparametric model, such as the one specified in Section 3.2 that puts no constraints on each Q sa except for having bounded support and a minimum variance. It also may be a semiparametric model or a parametric model. Denote the fraction of stage one subjects who are from subpopulation s ∈ S by p s , which we allow to be unknown before the trial starts. We denote the set of subpopulation proportions enrolled in stage one by p = {p s } s∈S . Let P denote the set of possible p. This could be unconstrained, or constraints can be imposed based on knowledge of possible enrollment proportions.
The joint distribution of the statistics T = T (1) , T (2) , which we denote by P (n) , is a function of the data generating distributions Q , the stage one subpopulation proportions p, and the sample size n. Implicitly, P (n) also depends on the prespecified quantities listed in Section 5.2, including the set of subpopulations S, the set of treatments A, the possible enrollment procedures for stage two E, the definition of the statistics T , and the decision rule D.
To simplify notation in what follows, we bundle Q and p together and denote the pair (Q , p) by Q. We let Q denote Q × P, which represents the class of all possible data generating distributions and stage one subpopulation enrollment proportions. We refer to each Q ∈ Q below, for brevity, as a data generating distribution.
Definition of asymptotic, worst-case, familywise type I error
The main problem addressed in this paper is to compute the asymptotic, worst-case familywise Type I error for a given design, which is defined as lim sup
where n → ∞ is shorthand for n 1 , n 2 → ∞, under the constraint given above in Section 5.2 that n 2 = rn 1 for some positive constant r. We say the asymptotic, familywise Type I error is strongly controlled at level α if the above expression is at most α.
Designs in which asymptotic, worst-case familywise Type I error is at most 0.05 guarantee control over familywise Type I error, uniformly over the data generating distributions, as sample size grows to infinity, which is a desirable property.
Assumptions on statistics
In our theorem below, we make two assumptions on the distributions of the statistics T . These assumptions are quite general, and we expect they will hold for a wide variety of designs. The first assumption in the theorem is that the vector of stage two statistics T (2) is independent of the stage one statistics T (1) , given the enrollment decision D(T (1) ) made just after stage one. This will hold, as is the case in the class of designs from Section 3, when the decision D(T (1) ) determines a subpopulation, or the total population, to obtain an independent random sample from in stage two, but otherwise the data in stage one has no effect on the enrollment procedure in stage two. This conditional independence assumption is broad enough to allow design changes such as early stopping, sample size adjustments, and adaptation of randomization probabilities, as long as these are preplanned changes based on statistics from stage one.
The second assumption in the theorem involves several parts, which require the introduction of additional notation. For any Q ∈ Q and sample size n, denote the mean of the first stage statistics T
(1) by µ
n (Q), and denote the distribution of the centered, stage one statistics
n (Q). We assume, for any Q ∈ Q, that G
n (Q) converges under P (n) to a zero mean, multivariate normal distribution G (1) (Q) as sample size n → ∞. We assume the vector of stage two, centered statistics, conditioned on the enrollment decision D(T (1) ), converges to a multivariate normal distribution. To make this precise, for any Q ∈ Q, for each potential stage two enrollment procedure ∈ E, let µ (2) n (Q, ) denote the conditional mean of the stage two statistics
Also, let G
n (Q, ) denote the conditional distribution under P (n) of the centered statistics
We assume for any Q ∈ Q and ∈ E, that G
n (Q, ) converges to a zero mean, multivariate normal distribution G (2) (Q, ) as sample size n → ∞. We allow the covariance of this limit distribution to depend on the data generating distribution Q.
We furthermore assume the above convergence of centered stage one and stage two statistics is uniform over data generating distributions Q ∈ Q. That is, we assume for all possible enrollment decisions ∈ E,
where C denotes the set of all Borel measurable, convex subsets of R t1+t2 . For the class of designs from Section 3, we prove in Section C.4 of the Supplementary Material that this assumption holds, using a generalized Berry-Esseen theorem from (Götze, 1991) .
Intuition behind theorem
The theorem below reduces the problem of computing asymptotic, worst-case, familywise Type I error to a more manageable optimization problem. We present some of the intuition behind the theorem.
Consider the case where data is generated according to a distribution Q ∈ Q. A familywise Type I error occurs, that is, at least one true null hypothesis is rejected, if the vector of statistics T is in any of the rejection regions R j for which the corresponding null hypothesis H 0j is true under Q. More concisely, a familywise Type I error occurs if and only if T ∈ j:Q∈H0j R j . We partition this event into more manageable pieces by intersecting it, for each possible stage two enrollment procedure ∈ E, with the event that our decision rule D says to enroll using . Define each such intersection by
By construction, on each such event A , the enrollment decision D(T (1) ) after stage one is always . It follows that the probability of A when T is generated by the adaptive design is the same as the probability of A were T instead generated by the fixed design that always makes enrollment decision regardless of the stage one data. Thus, by taking the intersection with each possible enrollment decision, we reduce the problem of computing familywise Type I error for an adaptive design to that of computing it for several fixed designs, which immensely simplifies our computations.
Combining the above with the assumption from Section 5.5 that the centered statistics converge to a multivariate normal, we succeed in reducing the original problem to one of computing, for each element of a class of easy to describe regions, the probability that a zero mean, multivariate normal distribution falls in that region. These regions are the ones in braces in (10), except that we need to center them; we define the centered versions of these regions, for each possible enrollment decision ∈ E, by
n (Q, ) ,
where for any set B ⊆ R m , and vector v ∈ R m , we define the shifted version of B as B −v = {x ∈ R m : x+v ∈ B}. The sets V (Q, n, ) figure prominently in the theorem below.
5.7 Theorem stating the equivalence of the asymptotic, worst-case, familywise Type I error to the solution of an optimization problem 
The expression (11) is an optimization problem, which involves finding the maximum value of the sum in the previous display, over the class of possible data generating distributions Q ∈ Q, and computing its lim sup as sample size n goes to infinity. A key to solving this optimization problem is that the limit distributions G
(1) (Q), G (2) (Q, ) and the set V (Q, n, ) often depend on the distribution Q only through a small number of scalar parameters. This simplifies the computation of the inner supremum in (11) to finding the supremum over the set of possible values of these scalar parameters. Evaluating the integral in (11) at a particular Q, n, and is often easy, using standard functions in statistical software for computing the distribution function of a multivariate normal distribution.
In Sections C-E of the Supplementary Material, we apply the above theorem to the class of enrichment designs in Section 3, to show each of these designs strongly controls asymptotic, familywise Type I error at level 0.05. An outline of the proof is given in Section C.3.
Discussion
A limitation of our results is that they are asymptotic, that is, our guarantees on Type I error control are in the limit as sample sizes in both stages of the adaptive design go to infinity. However, even in fixed designs, the standard t-test comparing means in the treatment and control groups has this issue; it is only guaranteed to have correct Type I error for testing null hypotheses such as those in Section 3, in the limit as sample size goes to infinity, unless parametric or other assumptions are made on the data generating distribution.
Our general method requires the ability to accurately compute values from a multivariate normal distribution function with statistical software. Our result for the class of designs in Section 3 only requires that we compute this for a bivariate normal distribution with accuracy to four decimal places. In general, the required accuracy will depend on the complexity of the design.
One important issue we did not address is the potential loss of generalizability in designs that focus on particular subpopulations. There is a risk that such designs will lead to conclusions applicable to a smaller population than a fixed design would have. However, an advantage of the above adaptive designs is that when treatments are truly only effective for one subpopulation, adaptive designs can have more power to discover this.
An area of future work related to the above adaptive designs is to determine the asymptotic, worst-case bias and mean squared error of maximum likelihood estimators, as well as to construct confidence intervals that are guaranteed to be asymptotically conservative. Important related work in this area includes (Jennison & Turnbull, 1984 , 1989 Proschan & Hunsberger, 1995; Lehmacher & Wassmer, 1999; Posch et al., 2005; Brannath et al., 2006; Wu et al., 2010) .
